ValueTheMarkets Logo
Stock Market Review for the Retail Investor
Features , Spotlight

This Company Has Developed a Range of Market-Leading Complementary Feed Products Specifically Formulated For Pets…

22 Feb 2021 | by: Patricia Miller

CRESO PHARMA (ASX:CPH)

Creso Pharma – The Rapidly Growing Firm at the Vanguard of the New Green Pet Product Market

The demand for cannabidiol products is growing.

And it’s growing fast.

The industry is already valued at over US$4.5 billion and is forecast to grow at an average rate of 22.2% year on year into 2025.

Every day, more and more people are discovering the benefits of this naturally sourced, hemp-based extract. 

The key for many is in realising that cannabidiol products don’t contain tetrahydrocannabinol, or THC, the component of cannabis that makes people high.

Indeed, cannabidiol products are not psychoactive, and work naturally with our body’s endocannabinoid system.

But us humans aren’t the only species to have an endocannabinoid system.

Many of our pets do too.

More and more people are beginning to see that cannabidiol products can help to relieve stress in an anxious Alsatian or reduce pain in a panicked Pomeranian, everyday.

In fact, it’s predicted that by 2025, 3-5% of all CBD sales in the US will be attributed to products designed for our pets.

Even Martha Stewart recently launched her own CBD product line for pets.

But a company called Creso Pharmatruly understands the opportunity here, and it is already stealing a march on much of the competition.

Not only has it established a range of CBD products for pets…

It has also recognised that as awareness of the market grows, owners will undoubtedly demand the best for their prized companions, and will soon see that many of the current market offerings just aren’t up to scratch.

Rushed Repackaging Isn’t Enough

You see, as it stands, there’s a problem with much of what is on offer in the CBD market when it comes to animal options.

Unlike Creso’s pet products, which have been specifically formulated for animals, the majority of the competition’s pet products are really just repackaged versions of the same products made for humans.

This isn’t right.

For a start, the products just aren’t as effective.

But then there’s also the issue of delivery…

Many of the current cannabinoid products on offer for pets come in oil form, which is difficult to administer.

The good news is:

Creso Pharmahas solved all of these problems in one.

Its bespoke range of pet-focused products are all specifically designed for animals…

They are all entirely natural…

And, crucially, they have no negative side effects.

What’s more, Creso Pharma has devised a proprietary way to deliver the cannabinoids themselves.

Its products come in the form of what it terms “complementary feeds”.

These are essentially granulated formulas that can be dissolved in water, mixed with food, or even fed to animals by hand.

Sales have already started at pace, with over 4 million doses of Creso Pharma’s Anibidiol product having been purchased. Not to mention the fact that the product range recently became the first CBD containing complementary feed products to be approved for use in Latin America.

It’s clear Creso Pharma is perfectly positioned to be dominant in the animal CBD space, and present investors with a great way to claim a stake in this growing market.

But the truth is, this is only one small part of this exciting investment opportunity…

Dig a little deeper and you’ll see Creso Pharma has all the hallmarks of a future giant…

Creso Pharma’s anibidiol pet CBD product.

READ OUR SPECIAL REPORT – TO HEAR ABOUT WHY CRESO PHARMA IS POSITIONED PERFECTLY TO RIDE THE SECOND “GREEN WAVE” IN CANNABIS AND CBD STOCKS


Creso Pharma – A Business Based on Three Pillars of Opportunity

CRESO PHARMA (ASX:CPH)

Creso Pharma has in fact built its business around three distinct pillars of opportunity.

Developing, manufacturing, and selling CBD products for animals is only one of those pillars.

You see, in addition to this, the company is also developing, manufacturing, and selling CBD products for humans too.

In fact, as well as innovating when it comes to providing CBD products for animals, it is also driving forward big changes in the way CBD products are made for us.

For example, as part of the research its expert scientists are carrying out, it has developed a way to consume CBD products that is significantly more efficient than what’s currently available from the competition.

Bottom line?

It means users can enjoy more of the medicinal benefits of CBD, surely making Creso Pharma’sproducts much more attractive to the market too.

What’s also interesting is that these two pillars of the business—the CBD products for humans and the ones for animals too—are managed out of Creso Pharma’s base of operations in Switzerland.

This positions the company perfectly for easier access into Europe and further afield, where CBD markets are only just beginning to realise their full potential.

Of course, one territory where CBD products, and cannabis products generally, have a much clearer path to going mainstream, is in the US.

So, it’s even more interesting that the third pillar of Creso Pharma’s business is its recreational cannabis operation, just across the US border, in Canada.

This arm is called Mernova Medicinal Inc., and it is managed by two former Canopy Growth Corp. (TSE:WEED) executives—Jack Yu and Isaac Allen.

Mernova is fully licensed to cultivate, process, and sell cannabis across Canada. In fact, it has been formally recognised by the Ontario Cannabis Retail Corporation as a supplier to Canada’s largest recreational market.

The division began retail sales in Canada in 2020, with purchase orders received from Nova Scotia, the Yukon, and New Brunswick, with upcoming orders anticipated from Ontario.

As part of a strategic push to diversify its product lines, Mernova will also be launching Hash and Pre-Roll Joint products into the rapidly growing Canadian recreational market in Q1, 2021.

Mernova’s cultivation facility

As regulation around cannabis continues to be relaxed in the US, this third pillar of the business provides another very attractive feather in Creso’s Pharma’s cap where investors are concerned.

Indeed, it has already attracted interest from one of the most successful people in the cannabis industry…

Canopy’s Former CEO Sees a Clear Path to Success

Though the opportunity to become a leader in the CBD for Animals market is exciting in itself…

It is obvious there is much more on the table where Creso Pharmais concerned.

It’s why one of the biggest names in the game has already joined the company as a strategic advisor.

We’re talking here about Bruce Linton.

In case you’ve not come across the name, it’s worth pointing out that as the founder, former Chairman of the Board, Chief Executive Officer, and co-Chief Executive Officer of Canopy Growth Corporation (TSE:WEED), Linton is without doubt one of the world’s leading cannabis industry executives.

During the six years he was at Canopy, he led it from a little known startup to a company with a market cap of roughly US$15 billion.

Today, he serves as Executive Chairman of GAGE Cannabis, and Director of MindMed (OTC:MMEDF).

And that’s not to mention that he is co-Chairman and former Chief Executive Officer of tech company Martello Technologies Group (CVE:MTLO), co-Founder of Ruckify Software, and an active investor in cannabis companies SLANG Worldwide (CSE:SLNG) and OG DNA Genetics.

So, this is a man who understands the market and has the foresight to see what’s coming.

And at Creso Pharmahe is supporting seasoned Big Pharma executives like:

  • Director and co-Founder Dr. Miri Halperin Wernli PhD, who has more than 25 years of strategic and operational leadership experience in the pharma and biomedical industries and is the current President of MindMed (OTC:MMEDF)…
  • Commercial and Market Access Director Jorge Wernli, a sought-after expert in developing access for both well-established pharmaceuticals and brand-new startups into different markets worldwide, from the EU and Latin America to Asia…
  • Commercial/Marketing Director Dr. Gian Trepp, a PhD in molecular biology and senior pharma marketing executive who is the engine driving Creso Pharma’s new product development.

It all adds up to a very bright future for Creso Pharma.

Indeed, with a huge opportunity for growth across all three pillars of the company…

With revenues steadily growing, and a truly global reach…

And with one of the most experienced and proven Boards in the business…

This could be the perfect time to join Linton and watch just how big a player Creso Pharma could become.



DOWNLOAD OUR EXCLUSIVE REPORT TO HEAR MORE ABOUT WHY CANNABIS EXPERT BRUCE LINTON IS BACKING CRESO PHARMA


PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by CRESO PHARMA LTD. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of five hundred thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.

Valuethemarkets.com, Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

    RNS Responses

    Is London’s mayor teeing up a UK cannabis revolution?

    The mayor of London plans to launch a review looking at decriminalizing cannabis amid a shift in public attitude. This could spell good times ahead for global cannabis stocks, as many weigh up their opportunities for future expansion.